Investigating Micro-Manipulation Procedures for Assisted Hatching Timing
United States75 participantsStarted 2025-04
Plain-language summary
This study aims to assess the clinical significance of cleavage stage (Day 3) assisted hatching compared to assisted hatching at the blastocyst stage (Day 5,6,7) of embryo development at the time of trophectoderm (TE) biopsy for patients undergoing in vitro fertilization (IVF) and preimplantation genetic testing for aneuploidy (PGT-A) for treatment of their infertility.
Who can participate
Age range18 Years – 42 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients undergoing an IVF cycle with plan for subsequent FET of a single euploid embryo
✓. \<4 2PNs prior to randomization
✓. Female partners age \<42 years old at start of VOR cycle
✓. Normal ovarian reserve:
✓. AMH ≥ 1.2 ng/mL
✓. AFC ≥ 8
✓. FSH ≤ 12IU/L
✓. BMI \<38
Exclusion criteria
✕. All patients who do not voluntarily give their written consent for participation
✕. Patients with a prior failed IVF cycle - defined as no blastocysts
✕. Patients with a history of more than one failed euploid embryo transfer
✕. Donor oocyte cycles
✕. Gestational Carriers
✕. Male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable)
✕. Use of surgical procedures to obtain sperm
What they're measuring
1
Blastulation Rate
Timeframe: 1 week after vaginal oocyte retrieval (VOR)
Trial details
NCT IDNCT06377917
SponsorReproductive Medicine Associates of New Jersey